DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SHILPA MEDICARE LTD (SHILPAMED) share price today?

SHILPA MEDICARE LTD (SHILPAMED) is trading at ₹620.25 on the NSE, down 2.76% on the day. Source: DocStoX.

What is the PE ratio of SHILPA MEDICARE LTD?

SHILPA MEDICARE LTD has a price-to-earnings (PE) ratio of 49.9 in the Healthcare sector.

What is the market capitalisation of SHILPA MEDICARE LTD?

SHILPA MEDICARE LTD has a market capitalisation of approximately ₹12,162 crore.

SHILPA MEDICARE LTD

SHILPAMED·NSE·Healthcare

₹620.25▼ -17.60 (-2.76%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹617.10

₹638.00

52W₹260

₹95052%

Open

₹635.00

High

₹638.00

Low

₹617.10

Prev Close

₹637.85

Volume

4.85L

VWAP

₹622.03

Snapshot

Key fundamentals

Market Cap

₹12,162 Cr

P/E Ratio

49.86Expensive

P/B Ratio

4.55

EPS

₹12.44

Book Value

₹132.00

ROE

9.40%Average

ROCE

11.00%Decent

Dividend Yield

0.16%

Debt / Equity

0.25Low

Face Value

₹1.00

52W High

₹949.90

52W Low

₹259.50

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹142

▼ 77.1%downside

Trading at ₹620 — 77% above our estimate

BearFair valueBull

₹121₹142₹192

/100

Business quality — Watch the fundamentals

Growth 55Profitability 49Efficiency 8Valuation 44

Plain English

Our view

A steady, established business
Low debt relative to equity
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

49.9Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

9.4%Average

Above 15% is considered healthy for Indian equities

ROCE

11.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.25Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹12,162 Cr

P/B

4.55

EPS

₹12.44

Div Yield

0.16%

What changed

Recent changes

Foreign investors+0.1% stake last quarter
Domestic institutions+0.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 49.9×

Growth

Steady

+14% rev CAGR

Profitability

Modest

9.4% ROE

Financial health

Rock solid

D/E 0.25

Momentum

N/A

No technicals

Today

Trading activity

Delivery %50.9%

Turnover₹3013.87L Cr

Trades22,450

VWAP₹622.03

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+13.7%

+11.3%

10Y

+7.9%

Profit

—

+10.7%

10Y

+9.4%

EPS

—

+6.5%

10Y

+6.3%

Profile

Cons

Stock is trading at 4.73 times its book value
The company has delivered a poor sales growth of 11.4% over past five years.
Company has a low return on equity of 5.53% over last 3 years.
Promoter holding has decreased over last 3 years: -9.88%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.11 pts; domestic institutions added 0.25 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

40%

Promoter

Promoters

40.1%0.00

Public

27.7%-0.10

FII / FPI

11.1%+0.11

DII

8.6%+0.25

Others

12.5%

Total shareholders

53,410-389 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter40.13%

FII11.08%

DII8.58%

Public27.70%

Others12.51%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions